#1 Clinical Trials Search in Europe

L-LEUCINE

L-Leucine, an essential amino acid, is emerging as a promising therapeutic agent in various medical conditions. Clinical trials are currently exploring its benefits in treating rare diseases like Diamond Blackfan Anemia and Niemann-Pick Disease, as well as common conditions such as depression. The unique properties of L-Leucine and its derivatives, including their role in protein synthesis and neurotransmitter regulation, make them valuable candidates for medical research. This article examines the current clinical trials investigating L-Leucine’s potential therapeutic applications, highlighting its mechanisms of action, dosing strategies, and preliminary results.

Table of Contents

What is L-Leucine?

L-Leucine is an essential amino acid, which means your body cannot produce it and must obtain it from food or supplements. It belongs to the group of branched-chain amino acids (BCAAs) and plays several important roles in the body. L-Leucine is unique among amino acids as it functions as a nutrient regulator of protein synthesis, particularly in skeletal muscle and adipose tissue [1].

This amino acid has been studied for various medical applications, ranging from rare genetic disorders to mental health conditions. Different forms of leucine are being investigated, including the standard L-Leucine form as well as modified versions such as N-Acetyl-L-Leucine and L-Leucyl-L-Leucine methyl ester (LLME) [2] [3].

L-Leucine in Diamond Blackfan Anemia

Diamond Blackfan Anemia (DBA) is a rare congenital syndrome characterized by red cell aplasia (failure to produce red blood cells), physical anomalies, short stature, and an increased risk of cancer. It is caused by mutations affecting genes that encode ribosomal proteins [1].

Clinical research suggests that L-Leucine may have therapeutic benefits for DBA patients. The current standard treatments for DBA include corticosteroids, chronic red blood cell transfusions, and hematopoietic stem cell transplantation—all of which can have significant complications [1].

L-Leucine appears to work as a translation enhancer, potentially helping to overcome the ribosomal insufficiency that characterizes DBA. Preclinical studies have shown that exposing DBA lymphocytes (a type of white blood cell) to high doses of L-Leucine can increase protein synthesis [1].

Recent clinical data has indicated that L-Leucine supplementation may increase hemoglobin levels and lead to transfusion independence in some patients with DBA and the related 5q-syndrome (which shares similar altered ribosome functions) [1].

L-Leucine in Mental Health Disorders

Research is exploring L-Leucine’s potential role in treating major depressive disorder (MDD), particularly in patients who exhibit increased inflammation [3] [2].

The mechanism behind L-Leucine’s potential antidepressant effects involves the kynurenine pathway. When activated by inflammation, this pathway can produce substances that are toxic to brain cells and may disrupt brain cell communication and function. L-Leucine may help block these toxic substances from entering the brain by competitively inhibiting kynurenine uptake via the large neutral amino acid transporter (LAT1) [2].

Clinical trials are investigating whether L-Leucine supplementation can improve several aspects of depression, including:

  • Overall depression severity
  • Anhedonia (inability to feel pleasure)
  • Fatigue symptoms
  • Psychosocial function
  • Psychomotor slowing (reduced physical movement and cognitive processing speed)

One study is specifically examining changes in brain chemistry, including glutamate levels and brain connectivity patterns in regions like the basal ganglia and prefrontal cortex, which are involved in mood regulation and motor control [2].

Another study is investigating whether L-Leucine has rapid antidepressant effects, potentially providing faster relief than conventional antidepressants, which typically take weeks to become effective [3].

N-Acetyl-L-Leucine for Neurological Disorders

N-Acetyl-L-Leucine is a modified form of L-Leucine that is being investigated for several rare neurological disorders characterized by problems with movement coordination (ataxia) [4] [5].

This compound is being studied in patients with:

  • Ataxia-Telangiectasia (A-T): A rare genetic disorder that affects the nervous system, immune system, and other body systems. Symptoms include progressive difficulty with coordinating movements (ataxia) [4].
  • Niemann-Pick Disease Type C (NPC): A rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances (lipids) inside cells. This leads to excessive accumulation of these substances within various tissues of the body, including brain tissue [5].

Clinical trials are measuring the effect of N-Acetyl-L-Leucine on:

  • Ataxia severity using standardized scales like the Scale for the Assessment and Rating of Ataxia (SARA)
  • Functional abilities through measures like the Spinocerebellar Ataxia Functional Index (SCAFI)
  • Overall disease severity and quality of life

These studies involve a crossover design where patients receive either N-Acetyl-L-Leucine or placebo for a period, then switch to the other treatment, allowing researchers to compare the effects within the same individuals [4] [5].

L-Leucyl-L-Leucine Methyl Ester in Immune Recovery

L-Leucyl-L-Leucine methyl ester (LLME) is another modified form of leucine being investigated to improve immune system recovery following stem cell transplantation [6].

After a stem cell transplant, patients often have severely compromised immune systems, leaving them vulnerable to infections. LLME is being studied as a way to accelerate immune reconstitution by treating donor lymphocytes (a type of white blood cell) before they are infused into the transplant recipient [6].

The procedure involves:

  1. Collecting blood cells from the donor
  2. Treating these cells with LLME in the laboratory
  3. Washing the cells to eliminate the LLME
  4. Administering the treated cells to the transplant recipient

The goal is to increase the patient’s CD4 cell count (a type of immune cell) to above 100, which appears to decrease the risk of infections [6].

Dosage and Administration

The dosage and administration of L-Leucine and its derivatives vary depending on the condition being treated and the specific form used:

  • For Diamond Blackfan Anemia: L-Leucine is administered orally at a dose of 700 mg/m² three times a day for a treatment course of 6 months [1].
  • For Major Depression: Studies have used various dosages:
    • 4.31 g/day of L-Leucine administered orally [2].
    • 4 grams of L-Leucine twice daily (8 g/day total) [3].
  • For Neurological Disorders (using N-Acetyl-L-Leucine):
    • For patients 13 years and older: 4 g/day total, administered as 3 doses per day [5].
    • For patients under 13: Weight-tiered doses [4] [5].

The medication is typically administered orally, often as granules in a sachet that can be mixed with water, orange juice, or almond milk to form a suspension [4] [5].

Potential Side Effects

Clinical trials are monitoring for potential side effects of L-Leucine and its derivatives. In studies of L-Leucine for depression, researchers are using standardized scales like the Frequency, Intensity, and Burden of Side-effect Rating (FIBSER) scale to assess adverse effects [3].

Since many of these uses are still experimental, the full side effect profile is not yet well-established. Patients participating in clinical trials are closely monitored for adverse reactions.

It’s important to note that L-Leucine should only be used under medical supervision, especially for treating medical conditions. If you’re interested in L-Leucine for a specific condition, talk to your healthcare provider about whether participating in a clinical trial might be appropriate for your situation [3] [2].

Condition Form of L-Leucine Dosage Primary Outcomes Measured Potential Benefits
Diamond Blackfan Anemia L-Leucine 700mg/m² three times daily for 6 months Hemoglobin levels, transfusion independence Increased protein synthesis, improved red blood cell production, potential reduction in transfusion requirements
Major Depression (Midlife) L-Leucine 4.31 g/day for 6 weeks Change in glutamate levels, brain connectivity, depression symptoms Blocking kynurenine pathway, preventing toxic substances from entering the brain, potential rapid antidepressant effects
Major Depressive Disorder L-Leucine 4 g twice daily for two weeks Change in depression severity (QIDS-SR score) Potential rapid reduction in depression symptoms, especially in patients with inflammation
Ataxia-Telangiectasia N-Acetyl-L-Leucine 2-4 g/day based on weight for 12 weeks Scale for Assessment and Rating of Ataxia (SARA) Improved muscle coordination, better quality of life, reduced neurological symptoms
Niemann-Pick Disease Type C N-Acetyl-L-Leucine 4 g/day for adults, weight-adjusted for children, for 12 weeks Scale for Assessment and Rating of Ataxia (SARA) Improved neurological function, better quality of life, reduced disease progression
Stem Cell Transplantation L-leucyl-L-leucine methyl ester (LLME) Used to treat donor lymphocytes before infusion Immune system recovery (CD4 cell counts) Accelerated immune system recovery following transplantation, reduced risk of infections

FAQ

  • What is L-Leucine and why is it being studied in clinical trials? L-Leucine is an essential amino acid that our bodies cannot produce, so we must obtain it from our diet. It's unique among amino acids because it plays important roles in protein synthesis and cellular signaling. In clinical trials, L-Leucine is being studied because research has shown it may help with several conditions including rare blood disorders like Diamond Blackfan Anemia, neurological conditions like Ataxia-Telangiectasia and Niemann-Pick Disease Type C, and even mental health conditions like depression. Its ability to enhance protein synthesis, potentially block harmful substances from entering the brain, and regulate various cellular processes makes it an interesting candidate for medical treatments.
  • How might L-Leucine help patients with Diamond Blackfan Anemia? In Diamond Blackfan Anemia (DBA), patients have mutations in genes that encode ribosomal proteins, leading to red cell aplasia (failure to produce red blood cells). L-Leucine may help because it acts as a translation enhancer, potentially improving ribosomal function. Studies have shown that L-Leucine can increase protein synthesis in cells affected by DBA. Clinical trials are examining whether L-Leucine supplementation at doses of about 700mg/m² taken three times daily can increase hemoglobin levels and reduce or eliminate the need for blood transfusions in these patients. Preliminary clinical data has shown promising results with some patients achieving transfusion independence after L-Leucine treatment.
  • What role might L-Leucine play in treating depression? Clinical trials are investigating L-Leucine's potential as an antidepressant based on its ability to affect brain chemistry. One mechanism being studied is L-Leucine's ability to block the kynurenine pathway, which can produce substances toxic to brain cells when activated by inflammation. These toxins may disrupt brain cell communication and contribute to depression symptoms. In midlife depression trials, researchers are giving participants about 4.3 grams of L-Leucine daily to see if it improves brain glutamate levels, connectivity, and reduces depression symptoms. Studies are particularly focused on depression with signs of inflammation and symptoms like anhedonia (inability to feel pleasure) and psychomotor slowing, which are often difficult to treat with conventional antidepressants.
  • What forms of L-Leucine are being tested in clinical trials? Several forms of L-Leucine are currently being tested in clinical trials. These include pure L-Leucine (the basic amino acid form), which is being studied in Diamond Blackfan Anemia and depression trials, typically administered as pills or powder. N-Acetyl-L-Leucine, a modified form of the amino acid, is being investigated for neurological conditions like Ataxia-Telangiectasia and Niemann-Pick Disease Type C, usually given as granules that are mixed with liquid. There's also L-leucyl-L-leucine methyl ester (LLME), which is being studied for its potential to improve immune system recovery following stem cell transplantation. Each form has different properties that may make it more suitable for specific conditions.
  • What are the typical doses of L-Leucine used in clinical trials? The dosage of L-Leucine varies depending on the condition being treated and the form being used. For Diamond Blackfan Anemia, trials are using about 700mg/m² three times daily (roughly 2.1g per day for an average adult). In depression studies, doses range from about 4.3 to 8 grams per day, typically divided into multiple doses. For the N-Acetyl-L-Leucine form used in neurological disorders, adults usually receive about 4 grams daily, while children receive weight-adjusted doses. These doses are much higher than what would be consumed in a regular diet, as the trials are testing therapeutic effects rather than simply addressing nutritional deficiencies. Most trials administer L-Leucine orally, either as pills, powders, or granules mixed with liquids.

Ongoing Clinical Trials on L-LEUCINE

  • Study on the Impact of Acetylcysteine and Drug Combination on Kidney Function in Living Donor Kidney Transplant Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • L-Leucine: An essential amino acid that the body cannot produce on its own and must be obtained from food or supplements. It plays important roles in protein synthesis and cellular signaling. In clinical trials, it's being investigated for treating various conditions including blood disorders and depression.
  • N-Acetyl-L-Leucine: A modified form of the amino acid L-Leucine that has an acetyl group attached. This form is being investigated for neurological conditions such as Ataxia-Telangiectasia and Niemann-Pick Disease Type C, potentially due to its improved ability to cross the blood-brain barrier.
  • Diamond Blackfan Anemia (DBA): A rare congenital syndrome characterized by red cell aplasia (failure to produce red blood cells), physical anomalies, short stature, and increased risk of malignancy. It's caused by mutations in genes that encode ribosomal proteins.
  • Ribosomal protein: Proteins that make up ribosomes, which are the cellular structures responsible for protein synthesis. Mutations in genes encoding these proteins are implicated in Diamond Blackfan Anemia.
  • Ataxia-Telangiectasia (A-T): A rare, neurodegenerative disorder characterized by progressive loss of muscle control (ataxia) and small, dilated blood vessels (telangiectasia) on the surface of the eyes and skin.
  • Niemann-Pick Disease Type C (NPC): A rare, progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances (lipids) inside cells, leading to an accumulation of these substances in various tissues, including the brain.
  • Kynurenine pathway: A metabolic pathway that breaks down the essential amino acid tryptophan. When activated by inflammation, this pathway can produce substances that are toxic to brain cells, potentially contributing to depression.
  • Anhedonia: The inability to feel pleasure in activities that were once enjoyable. It's a common symptom of depression and is being specifically measured in clinical trials of L-Leucine for depression.
  • Psychomotor slowing: A slowing of physical movements and thoughts, which is a common symptom in depression. It can affect speech, body movements, and reaction time.
  • Glutamate: A major excitatory neurotransmitter in the brain that plays important roles in learning and memory. Abnormal glutamate levels have been linked to various mental health conditions, including depression.
  • L-leucyl-L-leucine methyl ester (LLME): A compound derived from L-Leucine being studied for its potential to improve immune system recovery following stem cell transplantation.
  • Hemoglobin: A protein in red blood cells that carries oxygen from the lungs to the body's tissues. Hemoglobin levels are an important measure of response to treatment in Diamond Blackfan Anemia trials.
  • Complete response (CR): In Diamond Blackfan Anemia trials, this is defined as achieving a hemoglobin level greater than 9 g/dL and becoming independent of blood transfusions.
  • Partial response (PR): In Diamond Blackfan Anemia trials, this is defined as having a hemoglobin level less than 9 g/dL but with increased reticulocyte count greater than 1% and any increase in transfusion interval from baseline.
  • Scale for the Assessment and Rating of Ataxia (SARA): An 8-item clinical rating scale used to assess the severity of ataxia (lack of muscle coordination). It includes items related to gait, stance, sitting, speech, and coordination tests. Lower scores indicate improvement.
  • Clinical Global Impressions (CGI): A rating scale used in many clinical trials to assess the overall improvement or worsening of a patient's condition, as judged by a clinician, caregiver, or the patient themselves.

References

  1. https://clinicaltrials.gov/study/NCT02386267
  2. https://clinicaltrials.gov/study/NCT06580145
  3. https://clinicaltrials.gov/study/NCT03079297
  4. https://clinicaltrials.eu/trial/study-on-the-effects-of-n-acetyl-l-leucine-for-patients-with-ataxia-telangiectasia/
  5. https://clinicaltrials.eu/trial/study-on-n-acetyl-l-leucine-for-patients-with-niemann-pick-disease-type-c/
  6. https://clinicaltrials.gov/study/NCT00429039